PU-H71

DRUG5 trials

Sponsors

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Samus Therapeutics, Inc.

Conditions

LymphomaMetastatic Breast CancerMetastatic Solid TumorMyelofibrosisMyeloproliferative Neoplasms (MPN)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis

Phase 1

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

CompletedNCT01393509

Memorial Sloan Kettering Cancer CenterLymphoma, Metastatic Solid Tumor, Myeloproliferative Neoplasms (MPN)

Start: 2011-07-06End: 2023-03-23Updated: 2023-03-28

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

TerminatedNCT01581541

National Cancer Institute (NCI)Lymphoma, Solid Tumors

Start: 2011-04-26End: 2014-09-03Updated: 2017-10-04

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

CompletedNCT03166085

Memorial Sloan Kettering Cancer CenterMetastatic Breast Cancer

Start: 2017-05-23End: 2021-12-14Updated: 2021-12-20

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

TerminatedNCT03373877

Samus Therapeutics, Inc.Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis +1

Start: 2018-05-24End: 2020-03-10Updated: 2022-11-15

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

TerminatedNCT03935555

Samus Therapeutics, Inc.Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF)

Start: 2019-08-12End: 2022-11-04Updated: 2022-11-17

Related Papers

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Blood2022-11-154 citations

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Blood2019-11-136 citations

Phase I trial of the HSP-90 inhibitor PU-H71.

Journal of Clinical Oncology2015-05-2013 citations